DURVALUMAB atlantic TRIAL supports clinical activity and ASTRAZENECA’S OVERALL
Immuno-Oncology Strategy

Durvalumab demonstrated clinical activity and durable responses in 3rd-line or
later stage NSCLC patients; full data to be presented at a scientific congress
in 2016

Durvalumab monotherapy and combination trials on track in multiple cancers,
including 1st-line therapy for NSCLC, head & neck and bladder cancers

AstraZeneca today provided an update on preliminary findings from the ATLANTIC
trial of durvalumab as 3rd-line or later stage therapy in patients with locally
advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell
lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK
alterations. An initial analysis supports durvalumab’s clinical activity, with
durable responses and an established safety profile in these difficult-to-treat

ATLANTIC investigated the efficacy and tolerability of durvalumab in patients
who received at least two prior systemic treatment regimens including platinum
-based chemotherapy, and who have limited options for further therapy. A full
evaluation of the data is ongoing and the results will be presented at a
scientific congress in 2016.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief
Medical Officer at AstraZeneca, said: “As we have seen in other studies,
durvalumab has demonstrated expected clinical activity and durable response in
these heavily pre-treated patients. As previously communicated, the treatment
and regulatory landscape in lung cancer is evolving. We now believe it is
unlikely that ATLANTIC can be used for regulatory submission as a monotherapy,
but we will make that determination following a full analysis of the data.
Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast
advancing development programme focused primarily on novel combinations.”

A comprehensive durvalumab registration programme is underway across multiple
tumour types, stages of disease, and lines of therapy both as monotherapy and in
combination. This forms part of AstraZeneca’s late-stage immuno-oncology
programme and includes more than 9,000 patients in 16 clinical trials in lung,
bladder, head & neck, and other cancers,

To view the full document, please paste the following URL into the address bar
of your browser.